Drug development, clinical trials, and industry dynamics—what changes timelines, risk, and competitive positioning.
The first half of 2026 is seeing a surge in biopharma IPO activity, with companies like Braveheart Bio, Attovia Therapeutics, and Vogenx plotting competitive paths in cardiometabolic and immunology markets.
The first half of 2026 is seeing a surge in biopharma IPO activity, with companies like Braveheart Bio, Attovia Therapeutics, and Vogenx plotting competitive paths in cardiometabolic and immunology markets.
READ MORE
Pfizer has dropped another antibody-drug conjugate (ADC) for solid tumors from its pipeline, just weeks after a late-stage failure in non-small cell lung cancer. The move underscores ongoing challenges in ADC development and the broader landscape for novel cancer therapeutics.
Fairview Health Services reversed a staggering $315 million annual loss to achieve nearly $600 million in financial gains over two years. We explore the detailed leadership, workforce, and process strategies that defined this striking recovery.
AstraZeneca has acquired global rights to advance and commercialize Dizal Pharmaceutical’s Zegfrovy, a lung cancer drug already approved in the U.S., through a licensing agreement worth up to $1.5 billion.
BioSpace’s Q2 2026 Biopharma Job Market Report offers a comprehensive look at hiring trends, market shifts, and the evolving landscape of talent acquisition, with signs pointing toward sustained R&D activity and strategic recruitment.
EMD Serono has announced a reduction of 70 positions within its research and development staff, joining a broader wave of job cuts rippling across the biotech sector. The decision raises questions about the state of biopharma innovation and the employment landscape.
After a high-profile trial failure in glaucoma, Bausch + Lomb is redirecting its efforts to target another serious eye disorder—geographic atrophy—hoping to succeed where past contenders have failed.
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate has achieved a significant late-stage clinical win, validating their transpacific partnership and bolstering China’s growing role in cancer drug innovation.
Roche has halted two Huntington’s disease trials in collaboration with Ionis, signaling further difficulties for the biotech following another high-profile clinical failure.
GSK has ended its partnership with Alector after both companies failed to advance two critical antibody assets for neurodegenerative diseases. This decision highlights the persistent challenges in developing effective treatments for complex brain conditions.
Amgen has initiated a voluntary recall of almost 1 million bottles of its heart failure medication, Corlanor, following the discovery of a foreign substance in batches manufactured in Italy.
